• Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected in 2027
• Additional compassionate care work now initiated by the Nuclear Medicine Research Institute in South Africa utilizing 225Ac-loaded DLL3 Radio-DARPin, highlighting the versatility of DARPins as isotope agnostic vectors
• FIH imaging for MP0726, Radio-DARPin targeting MSLN, planned to start in H2 2026
• New target nomination in H2 2026, with two INDs planned in 2027 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.